Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery
Gynecologic Oncology Group · The University of Texas MD Anderson Cancer Center
Abstract
Inducing destruction of specific mRNA using small interfering RNA (siRNA) is a powerful tool in analysis of protein function, but its use as a therapeutic modality has been limited by inefficient or impractical delivery systems. We have used siRNA incorporated into the neutral liposome 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) for efficient in vivo siRNA delivery. In nude mice bearing i.p. ovarian tumors, nonsilencing siRNA tagged with the fluorochrome Alexa 555 was encapsulated into DOPC liposomes and shown to be taken up by the tumor as well as many major organs. Furthermore, DOPC-encapsulated siRNA targeting the oncoprotein EphA2 was highly effective in reducing in vivo EphA2 expression 48 hours…
Citation impact
- FWCI
- 12.76
- Percentile
- 100%
- References
- 56
Authors
7- CNCharles N. LandenCorresponding
Gynecologic Oncology Group, The University of Texas MD Anderson Cancer Center
- ACArturo Chávez‐Reyes
The University of Texas MD Anderson Cancer Center
- CDCorazon D. Bucana
The University of Texas MD Anderson Cancer Center
- RSRosemarie Schmandt
Gynecologic Oncology Group, The University of Texas MD Anderson Cancer Center
- MTMichael T. Deavers
The University of Texas MD Anderson Cancer Center
Topics & keywords
- Small interfering RNA
- In vivo
- Liposome
- Paclitaxel
- Cancer research
- RNA interference
- Medicine
- EPH receptor A2
- Good health and well-being